10/25/2007

Eli Lilly and Co. announced Wednesday its suspension of two small trials of prasugrel, a blood-thinning drug it developed with Daiichi Sankyo Co., due to dosage concerns. The company said the studies will remain suspended until their procedures are modified, but affirmed its plan to seek FDA approval for the drug by the end of the year.

Related Summaries